It stays mostly within the metabolic and endocrine systems and does not pose a known risk to the patients who receive plasma treatments
Ahrn B, Holst JJ, Mari A
I think patients deserve to know that rather than be sold certainty that does not yet exist
Is it patented
32, 33 Although numerous stimulants can affect PSCs including activation of some G-protein-coupled receptors (PGE2, angiotensin, CCK-A, CCK-B), 34, 35, 36, 37, 38, 39 it is unknown if GLP-1R occurs on PSC either in normal pancreas or pancreatic disease states or, whether PSCs are activated in AP or CP, or if it does occur, whether the GLP-1R agonists affect the PSC signaling cascade, growth or ability to release inflammatory mediators
Yes, many patients find that a medically guided weight reduction program enables them to overcome a weight loss plateau